Company Filing History:
Years Active: 2008-2010
Title: Christopher L Neal: Innovator in Cancer Research
Introduction
Christopher L Neal is a prominent inventor based in Houston, TX (US). He has made significant contributions to the field of cancer research, particularly in understanding the role of 14-3-3 zeta in hyperproliferative diseases. His work has led to the development of innovative methods for determining prognosis and potential therapeutic targets in various cancer types.
Latest Patents
Christopher L Neal holds 2 patents. His latest patents include "14-3-3 Zeta over-expression as a poor prognosis factor, and a therapeutic target in multiple cancer types." This patent outlines methods for determining prognosis in subjects with hyperproliferative diseases by assessing the expression and function of 14-3-3 zeta. Additionally, it describes methods for creating pharmaceutical agents that modulate apoptosis, which involves testing candidate substances for their ability to influence 14-3-3 zeta. The patent also details methods for treating subjects with hyperproliferative diseases, including breast cancer, by administering these pharmaceutical agents.
Career Highlights
Christopher L Neal is affiliated with the University of Texas System, where he continues to advance research in cancer therapeutics. His innovative approaches have garnered attention in the scientific community, contributing to a deeper understanding of cancer prognosis and treatment.
Collaborations
Some of his notable coworkers include Dihua Yu and Jun Yao, who collaborate with him on various research projects aimed at improving cancer treatment methodologies.
Conclusion
Christopher L Neal's work exemplifies the intersection of innovation and medical research, particularly in the fight against cancer. His contributions are paving the way for new therapeutic strategies that could significantly impact patient outcomes.